(SNPs) are the most common genetic variation contributing to the individual susceptibility to cancer (3). Following the finding of this relationship, a large number of candidate genes were studied in case-control studies (4).
Introduction
Cancer is a leading cause of death and a serious disease threatening public health in developed and developing countries worldwide. Based on the GLOBOCAN worldwide estimates for 2012, newly diagnosed cancers amount to 14.1 million and cancer-related deaths to 8.2 million (1) . It is well known that the etiology and development of cancer are complex, and can be affected by environmental and genetic factors (2) . In addition to exogenous factors, genetic variations are crucial in the development of cancer. Single nucleotide polymorphisms MDM4 polymorphisms and mutations have been frequently studied because of their impact on TP53 in some types of cancers. Most studies focused on MDM4 SNP34091 A>C (rs4245739). The MDM4 SNP34091 A>C polymorphism in the 3'-untranslated region of MDM4 creates a putative target site for miR-191-5p and miR-887-3p, which might lead to less expression of MDM4 (12, 13) . However, individual studies yielded inconsistent or conflicting findings because of heterogeneous data collection and inadequate sample sizes. To eliminate this inconsistency, we conducted a meta-analysis of all eligible case-control studies published to date and estimated the cancer risk of MDM4 polymorphisms.
Materials and methods

Publication search
The databases PubMed, Embase/Ovid and the Chinese National Knowledge Infrastructure (CNKI) were searched using the following search terms: "murine double minute 4", "MDM4", "polymorphism", "variants" and "cancer" to identify relevant articles on the subject. The last retrieval date was April 20, 2016. In addition, the references of the included studies were searched to identify additional potentially relevant studies. The language was restricted to English and Chinese. The included studies met the following inclusion criteria: 1) evaluation of the association between MDM4 SNP34091 A>C polymorphism and cancer susceptibility; 2) case-control study or cohort study; 3) the genotype distribution of the polymorphism in cases and controls was sufficient to estimate the odds ratios (ORs) with a 95% confidence interval (CI) and a p value. The main exclusion criteria were as follows: 1) case reports, review articles, and editorials; 2) no control population; 3) duplication of a previous publication; 4) insufficient available data.
Data extraction
Data extraction was carried out independently by 2 investigators. Disagreements were resolved by discussion. For each included study, the following information was collected: first author's name, year of publication, tumor type, country of study population, source of control, genotyping method, allele or genotype frequencies, and p value for Hardy-Weinberg equilibrium (HWE) of controls. The patient ethnicities were categorized as Caucasian, Asian or African. Publications that included more than 1 polymorphism were considered as separate studies. When more than 1 article was published by an author, the study with the largest number of participants was included.
Statistical analysis
In this meta-analysis, ORs with 95% CIs were calculated to assess the strength of the MDM4 SNPs and cancer susceptibility. The pooled ORs were calculated for allele comparison, dominant and recessive models, homozygote comparison and heterozygote comparison. The Z test was performed to estimate the significance of the pooled ORs, and p<0.05 was considered statistically significant. The HWE of each study describing control subjects was evaluated by the chi-square test at a significance level of p<0.05. The chi-square-based I 2 test and the p value of the Q test were used to evaluate the heterogeneity of the studies. As a guide, p>0.05 indicated a lack of heterogeneity, I 2 of <25% indicated low heterogeneity, I 2 ranging from 25% to 75% indicated moderate heterogeneity, and I 2 of >75% indicated high heterogeneity. If p>0.05, the pooled ORs were calculated using a fixed-effects model. Otherwise, a random-effects model was used. Furthermore, sensitivity analyses were performed by sequentially removing each eligible study. Publication bias of the literature was assessed with Begg's funnel plots. P<0.05 was considered representative of statistically significant publication bias. All p values were 2-sided, and statistical analyses were conducted using the STATA software version 12.0 (StataCorp).
Results
Characteristics of studies
Following the search strategy, 75 articles in PubMed, 26 articles in Ovid, and 22 articles in CNKI were identified. After removal of duplicates, 97 potentially relevant studies were retrieved. Based on the inclusion and exclusion criteria, 90 studies were excluded and 7 were included in this meta-analysis (14) (15) (16) (17) (18) (19) (20) . Three case-control studies involved 2 different geographical regions (15, 18, 19) , so they were considered as separate studies. The flow diagram is shown in Figure 1 . A total of 19,328 patients and 51,058 controls were included. The characteristics of the included studies are summarized in Table I .
Quantitative synthesis
Five different genetic models (allele, dominant, recessive, homozygote and heterozygote) were assumed to observe the association between the MDM4 rs4245739 polymorphism and cancer risk. The results are presented in Table II and Figure 2 . Significant associations were found in the allele model (C vs. A, OR = 0.715, 95% CI: 0.622-0.821, p = 0.000), dominant model (CC+AC vs. AA, OR = 0.684, 95% CI: 0.563-0.831, p = 0.000), recessive model (CC vs. AC+AA, OR = 1.139, 95% CI = 1.055-1.230, p = 0.001) and heterozygote model (AC vs. AA, OR = 0.687, 95% CI = 0.568-0.832, p = 0.000). No significant associations were found in the homozygote comparison (CC vs. AA: OR = 1.063, 95% CI: 0.842-1.342, p = 0.608).
Considering that geographical region and cancer type might bias the overall results, subgroup analyses were conducted according to these covariates in order to enhance the reliability and stability of our meta-analysis. With regard to cancer types, breast cancer failed to show any significant association. With regard to geographical region, 2 genetic models (allele and heterozygote) showed significant associations in Chinese populations.
Heterogeneity and sensitivity analyses
Heterogeneity was evaluated using the chi-square-based I 2 test; the results showed that heterogeneity existed in most of the overall comparisons and specific subgroup analyses (Tab. II). However, in the subgroup analysis by region, no significant heterogeneity was found in the China group. Sensitivity analysis was conducted to verify the effect of each study on the overall OR. Studies were sequentially omitted from the equation. The results showed that the pooled ORs of the 6 polymorphisms were not materially altered by the contribution of any individual study. These results showed that the meta-analysis was statistically robust (Fig. 3) .
Publication bias
Publication bias in all of the studies was assessed by Begg's funnel plot and Egger's test. Publication bias was found in 3 models (p = 0.025 for C allele vs. A allele; p = 0.000 for AC vs. AA; p = 0.000 for CC+AC vs. AA). For the remaining 2 models the graphical funnel plots were symmetrical and no publication bias was present (p = 0.161 for CC vs. AA; p = 0.168 for CC vs. AC+AA; Fig. 4 ). In the subgroup analysis based on geographical region, no publication bias was found.
Discussion
The TP53 tumor suppressor gene is a commonly mutated gene in human cancers (21) . This gene encodes a DNA-binding transcription factor that regulates sequence-specific target genes involved in cell growth inhibition, senescence and apoptosis, providing a powerful intrinsic defense against cancer (22) . MDM4 is a transcriptional regulator that binds to and inhibits p53 (6) . Gansmo et al (16) found that the MDM4 SNP34091 (rs4245739) polymorphism was not associated with risks for colon, lung and prostate cancer. However, Fan et al (17) found a significantly decreased non-Hodgkin lymphoma risk among carriers of the MDM4 rs4245739 C allele in Chinese. This research pooled these studies together. This is the first metaanalysis to detect the association between MDM4 rs4245739 polymorphism and cancer risk. In this meta-analysis, the association between MDM4 polymorphism and cancer was observed in the overall comparison and in specific subgroup analyses based on geographical region and cancer site.
The reason why the MDM4 rs4245739 polymorphism affects the cancer risk may be its influence on the miRNA binding site. This polymorphism creates a putative target site for miR-191-5p and miR-887-3p, such that MDM4 expression is affected by both miRNAs. miR-191-5p is overexpressed in osteosarcoma, colon cancer, and pancreatic cancer (23) (24) (25) , but its expression is relatively lower in prostate cancer (26) . The tissue-specific expression of miRNA may explain the different roles of the MDM4 rs4245739 polymorphism in cancer.
Considering the complexity of tumor etiology, we conducted subgroup analyses in this study. However, only the Heterogeneities between studies were found in this meta-analysis. Ethnicity is one of the most important factors affecting heterogeneity. In this gene polymorphism site, completely different genotype frequencies in Chinese and Norwegians were observed. In the subgroup analysis of China, no significant heterogeneities were found. In addition, tumor sites and characteristics also contribute to the heterogeneity.
This meta-analysis has some limitations. First, we must note that a publication bias was found in 3 model comparisons. So the results from these 3 models must be treated with caution. Second, the analysis did not consider gene environment interactions due to insufficient data. Finally, the data for each type of cancer were not sufficient, so future studies comprising larger subgroup populations are required.
In conclusion, the results of our meta-analysis show that the MDM4 SNP34091 A>C polymorphism may function as a protective factor against the cancer risk. Further studies with different ethnicities and large population sizes should be conducted to reach a comprehensive conclusion.
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